Skip to main content
Premium Trial:

Request an Annual Quote

Beckman Coulter Extends License to Critical Therapeutics' HMGB1 Technology

NEW YORK (GenomeWeb News) — Critical Therapeutics today said Beckman Coulter has exercised a licensing option to continue using its high mobility group box 1 technology.
CT said the companies penned a licensing deal in 2005 that gave BC the use of HMGB1 to develop an immunoassay to detect inflammatory diseases. HMGB1 has been identified as a possible mediator of tissue damage caused by inflammation.
Under the license, CT would receive a milestone payment on initial product sales and royalties on net sales, but specific financial terms of the agreement were not released.
CT CEO Frank Thomas said a HMBG1 blood-based test could be useful in diagnosing diseases such as multi-organ failure, sepsis, and inflammatory diseases such as rheumatoid arthritis.
CT also said it is working with MedImmune on an HMGB1 antibody clinical trials candidate.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.